A Clinical Intelligence Platform for Complex Patients
I built this because I could. Most patients in my situation cannot.
I am giving it to you so they do not have to.
Every health AI company does the same thing: summarize records within one hospital network. Surface billing codes. Flag drug interactions from a static list. None of them do this.
| Capability | ChatGPT Health | Copilot Health | Amazon Health | Claude Healthcare | Perplexity Health | This System |
|---|---|---|---|---|---|---|
| Cross-institutional contradiction detection | × | × | × | × | × | ✓ |
| Guideline compliance checking | × | × | × | × | × | ✓ |
| Clinical document generation | × | ~ | × | × | × | ✓ |
| Wearable causal inference | × | × | × | × | × | ✓ |
| Genomic variant classification | × | × | × | × | × | ✓ |
| Zero-config multi-patient analysis | × | × | × | × | × | ✓ |
The nearest funded competitor, Citizen Health ($44M Series A), covers roughly 30% of these capabilities.
Each card is a gap that persisted for months or years. A Sonar API query connected documented symptoms to published evidence. A doctor acted.
Cortisol 80 nmol/L never retested in 28 months
Post-HSCT endocrinopathy prevalence: 80% within 2 years. TSH alone misses central hypothyroidism.
Cortisol and ACTH ordered. Critically low confirmed.
GVHD graded "mild" with 3 organs involved
NIH 2014 criteria require moderate minimum for 3 organs. Scores changed without examinations.
Reclassified. Ruxolitinib started.
DLCO never checked despite anthracycline exposure
BOS screening requires serial DLCO, not just spirometry.
DLCO dropped 89% to 67%. BOS in 26.1% of lung volume.
ALAT 375 U/L uninvestigated for 20 months
Post-HSCT viral reactivation literature. Hepatitis E in immunosuppressed patients.
Hepatitis E diagnosed on stored serum.
Cardiac MRI never ordered despite idarubicin, ferritin 1247, tachycardia
Cardiac late effects after anthracycline exposure. Ferritin above 1000 as cardiac iron loading.
Diffuse myocardial edema. Lake Louise criteria met. LVEF 50.5%.
Brain MRI not ordered despite prolactin elevation, testosterone collapse
Post-HSCT CNS screening. Pituitary iron deposition after transfusion-dependent disease.
33 white matter lesions. 5.1x age-normal volume. Bilateral pallidal iron.
No autonomic testing in 26 months
IST diagnostic criteria. Post-HSCT dysautonomia. NIH 2022 cGVHD Task Force.
Oura data: RMSSD 8.7 ms. 94.4% below ESC threshold.
Testosterone ordered, never drawn for 14 months
Post-HSCT gonadal failure prevalence after myeloablative conditioning.
34.2 to 15.2 to 12.4 nmol/L. Collapsing.
A second patient sent his records. 55 documents from an Australian childhood leukemia survivor. 10 critical gaps found in 10 minutes. Zero configuration.
Blood cancer diagnosis at 33. Stem cell transplant November 2023. 26 months getting worse while 17 institutions said it was psychological.
482 Sonar queries across 8 domains in 56 days. 13 clinical outcomes. 5 international centers accepted the case.
Age 36. Leukemia at 14. Bilateral vertebral artery dissection with cerebellar stroke at 33. No cancer survivorship screening in 22 years.
The system analyzed everything in 10 minutes. The echocardiogram that was never done is being ordered. The survivorship screening that never happened is starting.
Two patients. Two countries. Two diseases. Same result: symptoms documented, workup never done, system found the gaps.
Zero configuration. Same system. Same result.
Perplexity identified the key papers, mapped mutation databases, and validated variant classification tools. The pipeline reclassified a variant of uncertain significance to pathogenic.
| Gene | Variant | ESM-2 Score | ACMG PP3 | Interpretation |
|---|---|---|---|---|
| DNMT3A | R882H | -8.383 | PP3 Strong | Hotspot in AML/MDS, disrupts catalytic domain |
| SETBP1 | G870S | -9.804 | PP3 Strong | SKI homology domain, disrupts degron motif |
| EZH2 | V662A | -2.966 | PP3 Supporting | SET domain loss-of-function. Reclassified VUS to Pathogenic. |
| PTPN11 | E76Q | -1.865 | PP3 Supporting | N-SH2 domain, disrupts autoinhibitory interface |
| IDH2 | R140Q | -1.478 | PP3 Benign/VUS | Gain-of-function oncometabolite. ESM-2 captures disruption, not gain. |
ClinVar submission SUB16087716. EZH2 V662A reclassified from VUS to Pathogenic. Zero PubMed hits for this specific variant. Perplexity identified Chase et al. 2020 establishing EZH2 SET domain loss-of-function.
ISMB 2026 Abstract #623 submitted. VarI track, flagship bioinformatics conference. 80.9% ClinVar concordance on 284 variants from 40 independent GENIE profiles. Zero false positives.
26,642 myeloid patients searched across 12 international databases. Zero matches for this mutation combination.
Tazemetostat contraindication predicted computationally. The drug was withdrawn globally on March 9, 2026.
Built on Oura Ring data. 13 analysis modules, 99,300+ biometric readings. Detected ruxolitinib response in 3 days (p=0.018). Predicted GVHD flare 31 days ahead.
Drug response detected from consumer wearable data in 3 days. Two patients. Two countries. Same platform.
Clinical decision support: $3.4-6.4B. Healthcare analytics: $53-64B. First mover ships before August 2, 2026, when EU AI Act high-risk rules create a compliance moat.
100,000-500,000 complex chronic disease patients represent a $149M-$239M ARR opportunity at maturity. Perplexity Computer already checks documents for logical consistency. It has not been deployed for clinical records.
Cardiologist, genomics, digital medicine. Maps to wearable and genomic capabilities.
NYU Langone digital health, AI clinical workflows. Maps to clinical document generation and contradiction detection.
Harvard, rare disease, genetics. Maps to genomic variant classification and complex patient management.
Oura's CMO invited their SVP Science and VP Product to a meeting after seeing the digital twin.
Oura is listed as a coming integration in Perplexity Health.
Open source through The Educational Equality Institute, a 501(c)(3) nonprofit serving 20,000+ beneficiaries across 37 countries.
Source code, query logs, clinical records, and specialist evaluations are available for review.